The sky is falling. The sky is falling. Seems like every day there’s another piece of news about the drop in Life Science venture capital (and here), with bouts of flagellation around each new quarterly press release from NVCA/PwC MoneyTree, Dow Jones VentureSource, or CB Insights. Everyone repeats the news with the same grim perspective and soon enough it just becomes well accepted fact, and runs the risk of being self-fulfilling. We all deride public investors for being too focused on quarterly numbers and yet here we are in the long-term venture industry whining about quarterly ups and downs. The reality is over the past decade Life Sciences venture capital has been incredibly stable source of capital.
To read the full, original article click on this link: Chicken Little & Life Science Venture Capital - Forbes
